Novelion Therapeutics Observes World Lipodystrophy Day
March 31 2017 - 6:00AM
Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a
biopharmaceutical company dedicated to developing new standards of
care for individuals living with rare diseases, today announced its
observance of World Lipodystrophy Day.
Chief Executive Officer Mary Szela said, "We support
Lipodystrophy United (LU), the Association of Families Affected by
Lipodystrophies in Spain, Europe & Latin America (AELIP), and
others in the lipodystrophy community in their mission to increase
awareness and diagnosis of this serious rare disease. Education is
an important step towards making an impact for people affected by
lipodystrophy, many of whom are undiagnosed and inadequately
treated.”
Lipodystrophy is a group of rare diseases characterized by a
lack of fat tissue. In some patients, it is genetic, and in others
it may be acquired. It can be characterized by a widespread lack of
fat tissue under the skin (generalized lipodystrophy) or limited
lack of fat tissue (partial lipodystrophy). This loss of fat tissue
causes a deficit in the hormone leptin leading to multiple medical
issues, including severe metabolic complications.
“We strive to facilitate support for lipodystrophy patients,
serving as an advocate to advance knowledge, treatment and research
of lipodystrophy. World Lipodystrophy Day is an important catalyst
to increase public awareness, with the goal of ultimately
increasing diagnosis and treatment of this serious rare disease,”
said Andra Stratton, president and founder of LU.
“World Lipodystrophy Day is an important initiative in order to
raise awareness and understanding of the challenges faced by these
patients and their families. Ultimately our goal is to improve
diagnosis, treatment and care for those affected by this rare
disease,” said Naca Eulalia Perez de Tudela Cánovas, president and
founder of AELIP.
To learn more about lipodystrophy, visit www.aelip.org,
www.lipodystrophyunited.org or http://www.lipodystrophy.co.uk.
About Novelion Therapeutics Novelion
Therapeutics is a biopharmaceutical company dedicated to developing
new standards of care for individuals living with rare diseases.
Novelion has a diversified commercial portfolio through its
indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes
MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate
for the potential treatment of inherited retinal disease caused by
underlying mutations in RPE65 or LRAT genes. The company seeks to
advance its portfolio of rare disease therapies by investing in
science and clinical development.
CONTACT:
Novelion Therapeutics Inc.
Amanda Murphy
Director, Investor Relations & Corporate Communications
857-242-5024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024